In lung adenocarcinoma patients, the expression of angiogenic proteins VEGF-A, VEGFR1 and VEGFR2 is significantly associated with KRAS mutations41 and possible therapy options comprise anti-angiogenic agents42. The gene discussed is KRAS; the disease is lung adenocarcinoma.